Clinical trials: Infectious Encephalitis
Japanese Encephalitis
Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
The objective is to assess the effect of a booster vaccination on immunogenicity of IC51 in terms of seroconversion rate.
- Trial name
- NCT00595309
- Testing
- IC51
- Where
- 3 sites in Austria, Germany
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam
A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced…
- Trial name
- JECEVAX-3 (NCT03282370)
- Testing
- JEVAX, JECEVAX
- Where
- 4 sites in Vietnam
- Volunteers
- 655 people, healthy volunteers welcome
- Sponsor
- National Institute of Hygiene and Epidemiology, Vietnam
Tick-borne Encephalitis
New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
The risk for tick borne encephalitis increases in Sweden. Together with an increased awareness of the possibility to acquire protection by vaccination, this has led to an increase in the number of doses of the vaccine distributed…
- Trial name
- NCT02318069
- Testing
- FSME-immune
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sormland County Council, Sweden
Encephalitis, Tick-Borne
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the first booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5…
- Trial name
- NCT00894686
- Testing
- FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infectious Disease, Yellow Fever
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
We hypothesize that a high CD4+ and CD8+ T cell count will reduce viremia upon challenge with a structurally heterologous virus, and correspondingly result in reduced magnitude of host response to challenge infection.
- Conditions
- Infectious Disease, Yellow Fever, Japanese Encephalitis, Viral Infection
- Trial name
- NCT05568953
- Testing
- Stamaril, Imojev, Ixiaro
- Where
- Singapore
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Tick-borne Encephalitis
Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
Antibody titers after tick-borne encephalitis (TBE) vaccination are less in elderly and vaccination breakthroughs are more common in this age group.
- Trial name
- NCT01361776
- Testing
- FSME-immune
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sormland County Council, Sweden
Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers
The purpose of the study is to evaluate the safety and immunogenicity of a novel Venezuelan Equine Encephalitis virus (VEEV) vaccine (V4020) for the first time in humans compared to placebo when administered by subcutaneous or…
- Trial name
- VEEV (NCT07088822)
- Testing
- V4020
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Medigen, Inc.
Tick-Borne Encephalitis
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
Tick-borne encephalitis (TBE) is a viral illness common in the Northern Hemisphere, especially Europe and Asia. TBE infection may lead to central nervous system problems and death.
- Trial name
- NCT00118924
- Testing
- LGT(TP21)/DEN4
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Progressive Multifocal Leukoencephalopathy
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Background: Progressive multifocal leukoencephalopathy (PML) is a severe viral infection of the brain. It is caused by JC virus.
- Trial name
- NCT01730131
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Japanese Encephalitis
Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children
This study has aim to describe the immune response to the second dose of Japanese encephalitis chimeric vaccine (JECV) in children previously vaccinated with one dose of JECV 5 years ago.
- Trial name
- NCT01954810
- Testing
- Japanese encephalitis chimeric vaccine (JECV)
- Where
- Thailand
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Khon Kaen University
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Japanese Encephalitis
Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51
The objective is to demonstrate equivalence of three commercial IC51 batches in terms of geometric mean titers for anti-JEV neutralizing antibody
- Trial name
- NCT00595465
- Testing
- Japanese Encephalitis purified inactivated vaccine
- Where
- 4 sites in Austria, Germany
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Tick Borne Encephalitis, Virus Diseases
Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
The aim of this study is to investigate the immunogenicity response in adults up to 10 years after one booster dose. Data collected from this study will allow for greater information to prescribers who administer TBE vaccine, so…
- Trial name
- NCT01562444
- Testing
- Blood draw
- Where
- Czechia
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease, Meningococcal Meningitis
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
This study compares the safety and immunogenicity profile of several travel vaccines given alone or concomitantly with MenACWY-CRM to healthy adults.
- Conditions
- Meningococcal Disease, Meningococcal Meningitis, Typhoid, Yellow Fever
- Trial name
- NCT01466387
- Testing
- Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine
- Where
- 5 sites in Czechia, Germany
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- Novartis
Japanese Encephalitis
This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population
This is an open-label, uncontrolled phase 4 study to assess the safety and immunogenicity of the Japanese encephalitis (JE) vaccine Ixiaro® (IC51) in an elderly population.
- Trial name
- NCT01158599
- Testing
- IXIARO®
- Where
- 5 sites in Austria, Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Japanese Encephalitis
Safety and Immunogenicity of JECEVAX in Young Children
A dose escalating study with 3 different dosing regimens of the studied vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the…
- Trial name
- NCT02816554
- Testing
- JEVAX, JECEVAX-1, JECEVAX-0.8
- Where
- 2 sites in Vietnam
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Hygiene and Epidemiology, Vietnam
Aseptic Meningitis
Aseptic Meningoencephalitis in Slovenia
The main objective of this study is: to establish etiology of acute aseptic meningitis/meningoencephalitis in Slovenia to assess the clinical course and outcome of tick-borne encephalitis and Lyme neuroborreliosis to characterize…
- Trial name
- NCT02328469
- Testing
- symptomatic therapy, Ceftriaxone or Doxycycline, questionnaire
- Where
- 2 sites in Slovenia
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Encephalitis, Tick-borne
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
The purpose of this study is to evaluate a) whether the seroconversion rates in children are equivalent after two and/or three partial vaccinations with TICOVAC 0.25 mL and TICOVAC 0.5 mL, and b) whether there is a difference in…
- Trial name
- NCT00161746
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 7 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Rabies, Japanese Encephalitis
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Establish non-inferiority of the immune response and evaluate the safety and tolerability of Rabies and Japanese Encephalitis (JE) vaccines given concomitantly or alone and according to either of 2 schedules for preexposure…
- Trial name
- NCT01662440
- Testing
- Rabies, Japanese Encephalitis
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 661 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines